Vaxcyte Inc

PCVX remains in a Stage 2 advancing regime with structural bullish momentum from the active Momentum Breakout pattern; however, price is extended above the rising EMAs and shows extreme overbought RSI and Options Score, indicating near-term exhaustion. We will Stalk for a pullback into the rising EMA zone to engage at more favorable levels.

• ↑Vax31 clinical data shows >94% serotype coverage.
• ↑Breakthrough therapy designation accelerates FDA review.
• ↓R&D spend rose 50% YoY to $400 M, increasing cash burn.